PAQR7 and glioblastoma: In glioblastoma, treatment with the specific mPRα agonist Org OD 02–0 induced an increase in U87 and U251 cell count by promoting the capacity of cells to proliferate; in addition, this treatment significantly promoted the capacity of U87 and U251 cells to migrate and invade [15].